 | • レポートコード：TPM-B04331 • 出版社/出版日：Transparency Market Research / 2017年10月 • レポート形態：英文、PDF、165ページ • 納品方法：Eメール • 産業分類：製薬・医療 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Global Site License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、心血管治療薬の世界市場について調べ、心血管治療薬の世界規模、市場動向、市場環境、薬剤分類別分析、流通経路別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、関連企業情報などをまとめた調査レポートです。 ・序文・調査範囲・調査手法 ・エグゼクティブサマリー ・心血管治療薬の世界市場動向 ・心血管治療薬の世界市場環境 ・心血管治療薬の世界市場規模 ・心血管治療薬の世界市場規模：薬剤分類別 ・心血管治療薬の世界市場規模：流通経路別 ・心血管治療薬の世界市場：地域別市場規模・分析 ・心血管治療薬の北米市場規模・予測 ・心血管治療薬のアメリカ市場規模・予測 ・心血管治療薬の中南米市場規模・予測 ・心血管治療薬のヨーロッパ市場規模・予測 ・心血管治療薬のアジア市場規模・予測 ・心血管治療薬の日本市場規模・予測 ・心血管治療薬の中国市場規模・予測 ・心血管治療薬のインド市場規模・予測 ・心血管治療薬の中東市場規模・予測 ・心血管治療薬のアフリカ市場規模・予測 ・競争状況・関連企業情報 |
Global Cardiovascular Drugs Market: Scope and Methodology
This report on the global cardiovascular drugs market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments.
The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment for the period from 2017 to 2025, considering the macro and micro environmental factors. Growth rates for each segment within the global cardiovascular drugs market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.
A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the market overview section. This section of the report also includes market attractiveness analysis that provides a thorough analysis of the overall competitive scenario in the global cardiovascular drugs market across regions.
Market revenue in terms of US$ Mn for the period between 2015 and 2025 along with the compound annual growth rate (CAGR %) from 2017 to 2025 are provided for all the segments, considering 2016 as the base year and 2015 as historic year. Market size estimations involved in-depth study of product features of different drug class and various pipeline products. Additionally, market related factors such as preference for self-medication, regional availability of specialty drugs, patent expiration of cardiovascular drugs & availability of generic drugs, projected launch of new drugs etc. in various geographies and historical year-on-year growth have been taken into consideration while estimating the market size.
Cardiovascular Drugs Market: Segmentation
Cardiovascular diseases are estimated to affect population across the globe. Cardiovascular diseases comprise diseases and disorders related to heart and blood vessels. Various drugs are available and are under development for treating cardiovascular diseases based on various indications, such as arrhythmia, myocardial infarction, atherosclerosis, etc.
Based on drug class, the global cardiovascular drugs market has been segmented into anti hyperlipidemics, anti-hypertensives, anti-coagulants, anti-fibrinolytics, anti-arrhythmic, and others. The others segment of drug class include drugs such as cardiac glycosides, antianginal drugs, and ant ischemic drugs. Anti-hypertensive drugs segment is projected to hold dominant share of global cardiovascular drugs market while anti-hyperlipidemics segment is likely to register steady growth during the forecast period from 2017 to 2025.
Based on the distribution channel, the global cardiovascular drugs market is segmented into retail pharmacies, hospital pharmacies and online pharmacies. High incidences of hospital visits for cardiovascular disease consultation and rise in emergency department visits is likely to contribute for steady growth of hospital pharmacies segment.
Cardiovascular Drugs Market: Geographical and Competitive Dynamics
Geographically, the global cardiovascular drugs market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In addition, the regions have been further segmented by major countries from each region.
The report also profiles major players in the cardiovascular drugs market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include AstraZeneca plc., Pfizer Inc., Novartis AG, Merck & Co., Inc., Bristol-Myers Squibb Company, Bayer AG, Sanofi, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd, Abbott Laboratories, Gilead Sciences, Inc., Johnson & Johnson, Astellas Pharma, Inc., Eli Lilly and Company, Otsuka Holdings Co., Ltd., Takeda Pharmaceutical Company Limited.
The global cardiovascular drugs market has been segmented as below:
Global Cardiovascular Drugs Market, by Drug Class
Anti hyperlipidemics
Antihypertensive
Anti-coagulants
Antifibrinolytic
Antiarrhythmic
Others ( Cardiac Glycosides, antianginal drugs, anti-ischemic drugs)
Global Cardiovascular Drugs Market, by Distribution Channel
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Global Cardiovascular Drugs Market, by Geography
North America
U.S.
Canada
Europe
Germany
France
U.K.
Spain
Italy
Rest of Europe
Asia Pacific
India
China
Japan
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of Middle East and Africa
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Cardiovascular Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Market Overview
4.3. Key Market Indicators
4.4. Market Dynamics
4.4.1. Drivers
4.4.2. Restraints
4.4.3. Opportunities
4.4.4. Trends
4.5. Cardiovascular Drugs Market Analysis and Forecast, 2017 – 2025
4.5.1. Market Revenue Projections (US$ Mn)
4.6. Porter’s Five Forces Analysis
4.7. Market Outlook
5. Global Cardiovascular Drugs Market Analysis and Forecasts, By Drug Class
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Key Trends
5.4. Market Value (US$ Mn) Forecast, By Drug Class
5.4.1. Anti Hyperlipidemics
5.4.2. Anti-hypertensive
5.4.3. Anti-Coagulants
5.4.4. Anti-fibrinolytics
5.4.5. Anti-arrhythmic
5.4.6. Others
5.5. Market Attractiveness, By Drug Class
6. Global Cardiovascular Drugs Market Analysis and Forecasts, By Distribution Channel
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Key Trends
6.4. Market Value (US$ Mn) Forecast, By Distribution Channel
6.4.1. Hospital Pharmacies
6.4.2. Retail Pharmacies
6.4.3. Online Pharmacies
6.5. Market Attractiveness, By Distribution Channel
7. Global Cardiovascular Drugs Market Analysis and Forecasts, By Region
7.1. Key Findings
7.2. Market Value (US$ Mn) Forecast, By Region
7.2.1. North America
7.2.2. Europe
7.2.3. Asia Pacific
7.2.4. Latin America
7.2.5. Middle East & Africa
7.3. Market Attractiveness, By Region
8. North America Cardiovascular Drugs Market Analysis and Forecast
8.1. Introduction
8.1.1. Key Findings
8.1.2. Key Trends
8.2. Market Value (US$ Mn) Forecast, By Drug Class
8.2.1. Anti Hyperlipidemics
8.2.2. Anti-hypertensive
8.2.3. Anti-Coagulants
8.2.4. Anti-fibrinolytics
8.2.5. Anti-arrhythmic
8.2.6. Others
8.3. Market Value (US$ Mn) Forecast, By Distribution Channel
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Size (US$ Mn) Forecast, By Country
8.4.1. U.S.
8.4.2. Canada
8.5. Market Attractiveness Analysis
8.5.1. By Drug Class
8.5.2. By Distribution Channel
8.5.3. By Country
9. Europe Cardiovascular Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.1.2. Key Trends
9.2. Market Value (US$ Mn) Forecast, By Drug Class
9.2.1. Anti Hyperlipidemics
9.2.2. Anti-hypertensive
9.2.3. Anti-Coagulants
9.2.4. Anti-fibrinolytics
9.2.5. Anti-arrhythmic
9.2.6. Others
9.3. Market Value (US$ Mn) Forecast, By Distribution Channel
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Size (US$ Mn) Forecast, By Country / Sub-region
9.4.1. Germany
9.4.2. U.K.
9.4.3. France
9.4.4. Spain
9.4.5. Italy
9.4.6. Rest of Europe
9.5. Market Attractiveness Analysis
9.5.1. By Drug Class
9.5.2. By Distribution Channel
9.5.3. By Country
10. Asia Pacific Cardiovascular Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.1.2. Key Trends
10.2. Market Value (US$ Mn) Forecast, By Drug Class
10.2.1. Anti Hyperlipidemics
10.2.2. Anti-hypertensive
10.2.3. Anti-Coagulants
10.2.4. Anti-fibrinolytics
10.2.5. Anti-arrhythmic
10.2.6. Others
10.3. Market Value (US$ Mn) Forecast, By Distribution Channel
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Market Size (US$ Mn) Forecast, By Country / Sub-region
10.4.1. Japan
10.4.2. China
10.4.3. India
10.4.4. Australia & New Zealand
10.4.5. Rest of Asia Pacific
10.5. Market Attractiveness Analysis
10.5.1. By Drug Class
10.5.2. By Distribution Channel
10.5.3. By Country
11. Latin America Cardiovascular Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.1.2. Key Trends
11.2. Market Value (US$ Mn) Forecast, By Drug Class
11.2.1. Anti Hyperlipidemics
11.2.2. Anti-hypertensive
11.2.3. Anti-Coagulants
11.2.4. Anti-fibrinolytics
11.2.5. Anti-arrhythmic
11.2.6. Others
11.3. Market Value (US$ Mn) Forecast, By Distribution Channel
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.4. Market Size (US$ Mn) Forecast, By Country / Sub-region
11.4.1. Brazil
11.4.2. Mexico
11.4.3. Rest of LATAM
11.5. Market Attractiveness Analysis
11.5.1. By Drug Class
11.5.2. By Distribution Channel
11.5.3. By Country
12. Middle East & Africa Cardiovascular Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.1.2. Key Trends
12.2. Market Value (US$ Mn) Forecast, By Drug Class
12.2.1. Anti Hyperlipidemics
12.2.2. Anti-hypertensive
12.2.3. Anti-Coagulants
12.2.4. Anti-fibrinolytics
12.2.5. Anti-arrhythmic
12.2.6. Others
12.3. Market Value (US$ Mn) Forecast, By Distribution Channel
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Online Pharmacies
12.4. Market Size (US$ Mn) Forecast, By Country / Sub-region
12.4.1. South Africa
12.4.2. GCC Countries
12.4.3. Rest of MEA
12.5. Market Attractiveness Analysis
12.5.1. By Drug Class
12.5.2. By Distribution Channel
12.5.3. By Country
13. Competition Landscape
13.1. Market Player – Competition Matrix (By Tier and Size of companies)
13.2. Company Profiles [Details – Overview, Product Overview Financials, Recent Developments, Strategy]
13.2.1. AstraZeneca Plc
13.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.1.2. Product Portfolio
13.2.1.3. SWOT Analysis
13.2.1.4. Financial Overview
13.2.1.5. Strategic Overview
13.2.2. Pfizer Inc.
13.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.2.2. Product Portfolio
13.2.2.3. SWOT Analysis
13.2.2.4. Financial Overview
13.2.2.5. Strategic Overview
13.2.3. Novartis AG
13.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.3.2. Product Portfolio
13.2.3.3. SWOT Analysis
13.2.3.4. Financial Overview
13.2.3.5. Strategic Overview
13.2.4. Merck & Co., Inc.
13.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.4.2. Product Portfolio
13.2.4.3. SWOT Analysis
13.2.4.4. Financial Overview
13.2.4.5. Strategic Overview
13.2.5. Bristol-Myers Squibb Company
13.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.5.2. Product Portfolio
13.2.5.3. SWOT Analysis
13.2.5.4. Financial Overview
13.2.5.5. Strategic Overview
13.2.6. Bayer AG
13.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.6.2. Product Portfolio
13.2.6.3. SWOT Analysis
13.2.6.4. Financial Overview
13.2.6.5. Strategic Overview
13.2.7. Sanofi
13.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.7.2. Product Portfolio
13.2.7.3. SWOT Analysis
13.2.7.4. Financial Overview
13.2.7.5. Strategic Overview
13.2.8. Boehringer Ingelheim GmbH
13.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.8.2. Product Portfolio
13.2.8.3. SWOT Analysis
13.2.8.4. Financial Overview
13.2.8.5. Strategic Overview
13.2.9. F. Hoffmann-La Roche Ltd
13.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.9.2. Product Portfolio
13.2.9.3. SWOT Analysis
13.2.9.4. Financial Overview
13.2.9.5. Strategic Overview
13.2.10. Abbott Laboratories
13.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.10.2. Product Portfolio
13.2.10.3. SWOT Analysis
13.2.10.4. Financial Overview
13.2.10.5. Strategic Overview
13.2.11. Gilead Sciences, Inc.
13.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.11.2. Product Portfolio
13.2.11.3. SWOT Analysis
13.2.11.4. Financial Overview
13.2.11.5. Strategic Overview
13.2.12. Johnson & Johnson
13.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.12.2. Product Portfolio
13.2.12.3. SWOT Analysis
13.2.12.4. Financial Overview
13.2.12.5. Strategic Overview
13.2.13. Astellas Pharma, Inc.
13.2.13.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.13.2. Product Portfolio
13.2.13.3. SWOT Analysis
13.2.13.4. Financial Overview
13.2.13.5. Strategic Overview
13.2.14. Eli Lilly and Company
13.2.14.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.14.2. Product Portfolio
13.2.14.3. SWOT Analysis
13.2.14.4. Financial Overview
13.2.14.5. Strategic Overview
13.2.15. Otsuka Holdings Co., Ltd.
13.2.15.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.15.2. Product Portfolio
13.2.15.3. SWOT Analysis
13.2.15.4. Financial Overview
13.2.15.5. Strategic Overview
13.2.16. Takeda Pharmaceutical Company Limited
13.2.16.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.16.2. Product Portfolio
13.2.16.3. SWOT Analysis
13.2.16.4. Financial Overview
13.2.16.5. Strategic Overview
Table 01: Global Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 02: Global Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 03: Global Cardiovascular Drugs Market Size (US$ Bn) Forecast, by Region, 2017–2025
Table 04: North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2025
Table 05: North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2025
Table 06: North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country, 2017–2025
Table 07: Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2025
Table 08: Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2025
Table 09: Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country, 2017–2025
Table 10: Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2025
Table 11: Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2025
Table 12: Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country, 2017–2025
Table 13: Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2025
Table 14: Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2025
Table 15: Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country, 2017–2025
Table 16: Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2025
Table 17: Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2025
Table 18: Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country, 2017–2025